A recent clinical study has shown that aspirin can lead to disease progression and early death in older people with advanced cancer.
American and Australian scientists published the results of their work in the Journal of the National Cancer Institute, according to Medikforum.
Thus, the researchers conducted a randomized, double-blind, placebo-controlled trial of daily intake of low doses of aspirin (namely, one hundred milligrams) in healthy elderly people. 19.1 thousand people from Australia and America over 70 years old who did not suffer from dementia, cardiovascular and other diseases at the time of the start of the study took part.
Some participants took aspirin, others a placebo, they were randomly selected. The observation lasted an average of 4.7 years.
Senior author Dr. Andrew T. Chan and others reported that 981 people who took aspirin and 952 who were given a placebo developed cancer. Thus, there were no statistically significant differences between groups in cancer development, but aspirin use was associated with a 19% increase in the risk of metastatic cancer and a 22% increase in the risk of stage 4 cancer.
Among participants who developed advanced cancer, aspirin use increased the risk of death compared to those taking placebo.